October 9, 2014
Congress of the South African Orthopaedic Association (SAOA), Cape Town – Dr. David North, an orthopaedic trauma surgeon associated with the University of Cape Town, presented a paper describing the results of the clinical trial sponsored by Carmell Therapeutics. The paper, entitled “First Clinical Use of a Novel Plasma-Based Biomaterial to Augment the Healing of Open Tibia Fractures”, was presented at the annual meeting of the South African Orthopaedic Association in September. Dr. North, who is a registrar at the University of Cape Town, was today awarded the GT du Toit Registrar Prize for the best registrar paper. The award is named after the renowned South African surgeon and is awarded annually by a panel of judges following the SAOA annual meeting. The registrar program in South Africa is analogous to residency training in the U.S.
“We are delighted that Dr. North received such great recognition for his paper”, said Alan West, Carmell’s president and chief executive officer. “The GT du Toit Registrar Prize is highly competitive and to add that award to Dr. North’s growing list of accomplishments is truly a great honor for him. We are especially pleased that he received this award after delivering his paper describing our clinical study.”
Dr. David North has been a registrar in Orthopaedic Surgery since 2012 at Groote Schuur Hospital in Cape Town, South Africa, which is affiliated with the University of Cape Town. Dr. North was one of the surgeons participating in this first-in-man clinical trial on the use of the REPAIR™ Putty for the treatment of open tibia fractures.
The REPAIR Putty incorporates a bio-active material manufactured from blood plasma and containing a concentration of natural plasma and platelet-derived regenerative factors that bathe the injured tissue as the material degrades over several weeks. The purpose of the study was to evaluate the safety and effectiveness of the putty to augment healing. Results demonstrated accelerated bone healing, more rapid wound closure and reduced infections, with no adverse events or safety concerns noted with the use of the putty.